Home » BAYER SAYS SCHERING OFFER UNCHANGED DESPITE RECENT DISAPPOINTMENTS
BAYER SAYS SCHERING OFFER UNCHANGED DESPITE RECENT DISAPPOINTMENTS
Bayer AG has informed Schering AG that its takeover offer remains unchanged despite the recall of a Ultravist product and the disappointing sargramostim clinical trial results.
Pharmaceutical
Business Review
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May